NICE finalises widened access to Alzheimer's drugs
This article was originally published in Scrip
NICE, the health technology institute for England and Wales, has published final guidance widening access to Pfizer/Eisai's Aricept (donepezil), Shire's Reminyl (galantamine), Novartis's Exelon (rivastigmine) and Lunbeck's Ebixa (memantine) for Alzheimer's disease. The guidance formally replaces older, contentious recommendations and follows much legal wrangling.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.